Schrödinger, Inc. (SDGR)
NASDAQ: SDGR · Real-Time Price · USD
19.53
-0.80 (-3.94%)
At close: Aug 1, 2025, 4:00 PM
19.65
+0.12 (0.61%)
After-hours: Aug 1, 2025, 7:55 PM EDT
Company Description
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications.
The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries.
The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations.
It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates.
Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
Schrödinger, Inc.
| Country | United States |
| Founded | 1990 |
| IPO Date | Feb 6, 2020 |
| Industry | Health Information Services |
| Sector | Healthcare |
| Employees | 891 |
| CEO | Ramy Farid |
Contact Details
Address: 1540 Broadway, 24th Floor New York, New York 10036 United States | |
| Phone | 212 295 5800 |
| Website | schrodinger.com |
Stock Details
| Ticker Symbol | SDGR |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001490978 |
| CUSIP Number | 80810D103 |
| ISIN Number | US80810D1037 |
| Employer ID | 95-4284541 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Ramy Farid Ph.D. | Chief Executive Officer, President and Director |
| Dr. Karen Akinsanya Ph.D. | President, Head of Therapeutics Research & Development and Chief Strategy Officer and Partnerships |
| Dr. Richard A. Friesner Ph.D. | Co-Founder, Scientific Advisory Chairman and Director |
| Kenneth Patrick Lorton | Executive Vice President, Chief Technology Officer and Chief Operating Officer of Software |
| Dr. Robert Lorne Abel Ph.D. | Executive Vice President, Chief Scientific Officer of Platform and Head of Modeling Research & Development |
| Prof. William Goddard III | Co-Founder and Scientific Advisor |
| Richie Jain | Executive Vice President, Chief Financial Officer and Treasurer |
| Jenny Herman | Chief Accounting Officer |
| Shane Brauner | Executive Vice President and Chief Information Officer |
| Jaren Irene Madden | Chief Corporate Affairs Officer and Head of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 18, 2025 | SCHEDULE 13G/A | Filing |
| Jun 18, 2025 | 8-K | Current Report |
| May 20, 2025 | 8-K | Current Report |
| May 19, 2025 | 8-K | Current Report |
| May 7, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| May 7, 2025 | 10-Q | Quarterly Report |
| May 7, 2025 | 8-K | Current Report |
| Apr 24, 2025 | ARS | Filing |
| Apr 24, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 24, 2025 | DEF 14A | Other definitive proxy statements |